

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM585126

| | | | |
|---|------------------------------------|-------------------------|-------------------------|
| SUBMISSION TYPE: | NEW ASSIGNMENT | | |
| NATURE OF CONVEYANCE: | RELEASE OF SECURITY INTEREST | | |
| CONVEYING PARTY DATA | | | |
| Name | Formerly | Execution Date | Entity Type |
| SILICON VALLEY BANK | | 07/06/2020 | Corporation: CALIFORNIA |
| RECEIVING PARTY DATA | | | |
| Name: | CLEARSIDE BIOMEDICAL, INC. | | |
| Street Address: | 900 North Point Parkway, Suite 200 | | |
| City: | Alpharetta | | |
| State/Country: | GEORGIA | | |
| Postal Code: | 30005 | | |
| Entity Type: | Corporation: DELAWARE | | |
| PROPERTY NUMBERS Total: 7 | | | |
| Property Type | Number | Word Mark | |
| Serial Number: | 88221046 | XIPERE | |
| Serial Number: | 87897002 | SCS MICROINJECTOR | |
| Serial Number: | 87896124 | XIPERE | |
| Serial Number: | 86636301 | SCS | |
| Serial Number: | 85639727 | CS | |
| Serial Number: | 85561295 | CLEARSIDE BIOMEDICAL | |
| Serial Number: | 85561286 | CS CLEARSIDE BIOMEDICAL | |
| CORRESPONDENCE DATA | | | |
| Fax Number: | 7038362021 | | |
| <i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i> | | | |
| Phone: | 7038366620 | | |
| Email: | bassam.ibrahim@bipc.com | | |
| Correspondent Name: | Bassam N. Ibrahim | | |
| Address Line 1: | 1737 King Street, Suite 500 | | |
| Address Line 4: | Alexandria, VIRGINIA 22314-2727 | | |
| ATTORNEY DOCKET NUMBER: | 0080003/115/101/102/69/3/ | | |
| NAME OF SUBMITTER: | Bassam N. Ibrahim | | |
| SIGNATURE: | /Bassam N. Ibrahim/ | | |

OP \$190.00 88221046

DATE SIGNED:

07/07/2020

Total Attachments: 5

source=Clearside-SVP IP Release of Security Interest#page1.tif

source=Clearside-SVP IP Release of Security Interest#page2.tif

source=Clearside-SVP IP Release of Security Interest#page3.tif

source=Clearside-SVP IP Release of Security Interest#page4.tif

source=Clearside-SVP IP Release of Security Interest#page5.tif

RELEASE OF SECURITY INTEREST

This Release of Security Interest ("**Release**") is executed as of July 6, 2020, by SILICON VALLEY BANK, a California Corporation, as collateral agent ("**Assignor**"), for the benefit of CLEARSIDE BIOMEDICAL, INC., a Delaware corporation ("**Assignee**").

RECITALS

WHEREAS, Assignee granted and pledged certain security interests in the intellectual property described on Exhibit A and Exhibit B attached hereto (collectively, the "**Intellectual Property**") to the Assignor pursuant to the Loan and Security Agreement, dated as of May 14, 2018 (as amended, restated, supplemented or otherwise modified from time to time, the "**Security Agreement**"), and recorded with the U.S. Patent and Trademark Office on August 29, 2019 at Reel/Frame 050217/0270 and Reel/Frame 6733/0277.

WHEREAS, Assignor wishes to release and reassign all interest that Assignor may have in the Intellectual Property as granted pursuant to the Security Agreement.

NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Assignor hereby states as follows:

1. Release of Security Interest. Assignor and its successors, legal representatives and assigns, hereby totally and permanently terminates, releases and discharges any and all security interests that it has pursuant to the Security Agreement in

(a) any and all patents, patent applications and other patent rights and any other governmental authority-issued indicia of invention ownership, including the patents listed in Exhibit A hereto, and all reissues, divisions, continuations, continuations-in-part, renewals, extensions and reexaminations thereof and amendments thereto (the "**Patents**"); and

b) any and all trademarks, service marks, trade names, brand names, logos, trade dress, design rights and other similar designations of source, whether registered or unregistered, including the trademark registrations and applications set forth in Exhibit B hereto, together with the goodwill connected with the use thereof and symbolized thereby and all extensions and renewals thereof (the "**Trademarks**").

2. Disclaimer of Any Other Interest. Assignor and its successors, legal representatives and assigns, hereby totally and permanently terminates, releases and discharges all other right, title, and interest (if any) it may have in the Intellectual Property.

[SIGNATURE PAGE FOLLOWS]

IN WITNESS WHEREOF, Bank has caused this Release to be duly executed and delivered by its officer thereunto duly authorized as of the date first above written.

ASSIGNOR:

SILICON VALLEY BANK


DocuSigned by:

By: _____
Name: M Scott McCarty
Title: Director

EXHIBIT A

Patents

| <u>Description</u> | <u>Registration/ Application Number</u> | <u>Registration/ Application Date</u> |
|---|---|---|
| Apparatus and methods for drug delivery using microneedles | 15619065 | 6/9/17 |
| Apparatus and methods for drug delivery using multiple reservoirs | 10188550 | 1/29/19 |
| Apparatus and methods for ocular injection | 9539139 | 1/10/17 |
| Apparatus and methods for ocular injection | 9180047 | 11/10/15 |
| Apparatus and methods for ocular injection | 9636253 | 5/2/17 |
| Apparatus and methods for ocular injection | 9770361 | 9/26/17 |
| Apparatus and methods for ocular injection | 9937075 | 4/10/18 |
| Variable diameter cannula and methods for controlling insertion depth for medicament delivery | 9956114 | 5/1/18 |
| Medical injector for ocular injection | D750223 | 2/23/16 |
| Ocular injection kit, packaging, and methods of use | 15427823 | 2/8/17 |
| Devices and methods for adjusting the insertion depth of a needle for medicament delivery | 15675035 | 8/11/17 |
| Methods and devices for the treatment of ocular diseases in human subjects | 9636332 | 5/2/17 |
| Methods and devices for the treatment of ocular diseases in human subjects | 9572800 | 2/21/17 |
| Methods and devices for the treatment of ocular diseases in human subjects | 9931330 | 4/3/18 |
| Methods and devices for the treatment of ocular diseases in human subjects | 15830727 | 12/4/17 |
| Apparatus and formulations for suprachoroidal drug delivery | 11709941 | 2/21/07 |
| Apparatus and formulations for suprachoroidal drug delivery | 15398538 | 1/4/17 |
| Device for ocular access | 15872206 | 1/16/18 |
| Apparatus and methods for ocular injection | 15946838 | 4/6/18 |
| Apparatus and methods for ocular injection | 16381213 | 4/11/19 |

| | | |
|---|------------------|----------|
| Device for ocular access | 13273775 | 10/14/11 |
| Apparatus and formulations for suprachoroidal drug delivery | 13842218 | 3/15/13 |
| Apparatus and formulations for suprachoroidal drug delivery | 13842288 | 3/15/13 |
| Apparatus and methods for drug delivery using microneedles | 14424685 | 2/27/15 |
| Methods and devices for the treatment of ocular diseases in human subjects | 14441151 | 5/6/15 |
| Device for ocular access | 14821310 | 8/7/15 |
| Methods and devices for the treatment of ocular diseases in human subjects | 15454636 | 3/9/17 |
| Formulations for the Suprachoroidal Space of an Eye and Methods | 16318804 | 1/18/19 |
| Systems and Methods for Ocular Drug Delivery | 16178162 | 5/2/17 |
| Systems and Methods for Delivering Drugs to Retinal Tissue | PCT/US2017065796 | 12/12/17 |
| Methods and Devices for the Treatment of Ocular Diseases in Human Subjects | 16041067 | 7/20/18 |
| Methods and Devices for the Treatment of Ocular Diseases in Human Subjects | 16124407 | 9/7/18 |
| Methods and Devices for Treating Posterior Ocular Disorders | 15319045 | 6/17/15 |
| Gene Therapy for Ocular Improvement | 62748788 | 10/22/18 |
| Gene Therapy for Ocular Improvement | PCT/US2018062712 | 11/28/18 |
| Compositions and Methods for Treating Noninfectious Uveitis | 62638744 | 3/5/18 |
| Compositions and Methods for Treating Noninfectious Uveitis | 62793562 | 1/17/19 |
| Compositions and Methods for Treating Noninfectious Uveitis | 16292845 | 3/5/19 |
| Thalidomide Derivatives and Methods of Use Thereof in Ocular Disorders | 62769659 | 11/20/18 |
| Plasma Kallikrein Inhibitors and Methods of Use Thereof in Ocular Disorders | 62830802 | 4/8/19 |
| Injectable Triamcinolone Formulations | 62834554 | 4/16/19 |

EXHIBIT B

Trademarks

| <u>Description</u> | <u>Registration/ Application Number</u> | <u>Registration/ Application Date</u> |
|-------------------------|---|---|
| XIPERE | 88221046 | 12/7/18 |
| SCS MICROINJECTOR | 87897002 | 4/27/18 |
| XIPERE | 87896124 | 4/27/18 |
| SCS | 86636301 | 5/20/15 |
| CS | 85639727 | 5/31/12 |
| CLEARSIDE BIOMEDICAL | 85561295 | 3/6/12 |
| CS CLEARSIDE BIOMEDICAL | 85561286 | 3/6/12 |